Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Octreotide may be an effective treatment for malignant ascites. It is not yet
known whether octreotide is more effective than a placebo in treating malignant ascites.
PURPOSE: This randomized phase III trial is studying octreotide to see how well it works
compared to placebo in treating patients with cancer-related malignant ascites.